Reiche, Dania Birte,Haag-Diergarten, Silke,Hennings, Leah Jeanette,Kley, Saskia,Traas, Anne M.
申请号：
AU2020201551
公开号：
AU2020201551A1
申请日:
2020.03.03
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020201551A120200319.pdf#####ABSTRACT: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.WO 2015/091313 PCT/EP2014/077677 1/15 Figure 1 1000 Compound A ng/mL plasma 100 10 1 Urine gluc/crea 0 5 10 15 20
